Colombia's Cannabis Exporters Are Stuck in a Four-Agency Maze

October 14, 2026

Photo by Juan Manuel Núñez Méndez via Unsplash.

Walk into almost any policy briefing on Latin American cannabis and Colombia gets held up as the hemisphere's most liberalized cultivation regime. On paper, that reputation is earned: the country permits large-scale outdoor cultivation of high-THC cannabis, has issued thousands of licenses, and sits on an equatorial growing advantage that Canadian and European producers would kill for. And yet almost none of that licensed capacity is turning into actual export revenue. Asocolcanna, the industry's main trade association, put real numbers on the gap in 2024: of roughly 15,000 hectares licensed for psychoactive cultivation, only about 17 were actually planted. Of some 3,000 total licensees across the country, just 18 managed to export commercially that year.

Fedesarrollo, the Bogotá-based economic research center, had projected the country should be exporting something on the order of $800 million annually given its licensed capacity and agronomic conditions. Actual 2024 exports landed around $30 million -- a shortfall of more than 95%. None of this traces back to a restrictive cultivation law. Colombia's statute is, if anything, generous by regional standards. The problem sits downstream, in a four-agency approval chain that every psychoactive shipment has to clear before it can legally leave the country, and in particular at one agency -- ICA, the Colombian Agricultural Institute -- that has become the narrowest point in that chain.

The Four-Agency Gauntlet Every Shipment Must Clear

Getting a kilo of cannabis flower or extract out of Colombia legally means satisfying four separate government bodies, each with its own paperwork, its own review timeline, and its own definition of what counts as complete. The Ministerio de Justicia handles the front end: cultivation licenses and seed licensing, the permission to grow the plant and propagate it in the first place. That's the easy part, relatively speaking, and it's why licensing numbers look so robust. The Ministerio de Salud takes over once raw material becomes a derivative -- oils, isolates, distillates -- issuing the manufacturing licenses required before anything gets processed into a sellable product.

INVIMA, Colombia's national food and drug regulator, handles sanitary registration for finished products, the step that confirms a product meets health and safety standards for sale or export. Then there's ICA, which controls phytosanitary certification for any plant-origin export and additionally requires that the specific cultivar being shipped appear in the National Register of Commercial Cultivars, known by its Spanish acronym RNCC. Finally, the Fondo Nacional de Estupefacientes -- the FNE, Colombia's national narcotics fund -- separately authorizes the actual export quota for each shipment, a per-batch sign-off that sits on top of everything else. And even after all four domestic approvals are in hand, the destination country still has to issue its own import permit before product can physically move.

Each additional agency in that sequence isn't just an extra form to fill out -- it's an independent point of failure with its own backlog, its own staffing constraints, and its own interpretation of requirements that can shift between application cycles. A single missing registration, one unlisted cultivar, one quota request stuck in queue, can stall an entire harvest indefinitely. Growers describe watching product age past its useful shelf life while paperwork sits untouched in a different ministry's inbox.

Why ICA Specifically Is the Pinch Point

Photo by CRYSTALWEED cannabis via Unsplash.

Of the four agencies, ICA has become the one exporters talk about most, and for a specific structural reason: its approval is mandatory only for cannabis that tests at 1% THC or higher, which ties export eligibility directly to whether a given cultivar is listed in the RNCC. If a cultivar isn't on that register, it cannot be exported -- full stop -- regardless of how clean the cultivation license is or how compliant the farm's other paperwork looks. A grower can hold every other document in order and still be stuck because the specific genetic variety in the ground has never been formally registered.

That bottleneck has gotten more complicated rather than less in the last year. Decree 1138 of 2025 restructured the licensing landscape by replacing the old export-only license with a combined national use and export license, opening a domestic flower market that didn't really exist before in a regulated form. ICA now oversees phytosanitary compliance not just for product headed abroad but for this new domestic market too, and the decree gave the agency a five-month window to issue its own technical cannabis regulations spelling out how that oversight will actually work.

The practical effect is that ICA's limited technical staff and review capacity now have to cover two overlapping jobs at once -- policing a brand-new domestic flower trade and continuing to certify export shipments -- without a corresponding increase in resources. Industry voices describe an agency trying to modernize its technical framework in real time while the backlog of cultivar registrations and phytosanitary reviews keeps growing. It's not that ICA is being obstructionist; it's that one agency has been handed an expanding mandate without the staffing to match it, and exporters are the ones sitting in the queue.

The Numbers Behind the Bottleneck

Colombia's cannabis sector shows a massive gap between licensed capacity and actual activity: only a tiny fraction of licensed hectares are cultivated and just a few dozen million dollars in exports have materialized against an $800M potential market.

The scale of the mismatch between Colombia's licensing capacity and its actual export performance is worth sitting with. Camilo De Guzmán, president of Asocolcanna, laid out the figures in 2024 that have since become the reference point for anyone trying to explain what's actually happening in the industry: 15,000 hectares licensed for psychoactive cultivation against roughly 17 hectares that were actually planted and harvested. That's not a rounding error -- it's a utilization rate well under one percent of licensed land.

The licensee numbers tell a similar story from a different angle. Colombia has issued licenses to around 3,000 cannabis operators nationally. Of those, only 18 managed to export commercially in 2024. Put another way, fewer than one in 150 licensed operators actually got product out the door and sold internationally -- commercial export success sitting below 1% of the total licensee pool, a figure De Guzmán cited explicitly when framing the scale of the problem for policymakers.

Fedesarrollo's macro estimate puts a dollar figure on what that gap costs the country: an industry with the licensed capacity to generate something close to $800 million in annual exports instead produced around $30 million in 2024. That's roughly 4% of projected potential. None of these numbers suggest a demand problem -- international buyers for Colombian cannabis derivatives exist and have existed for years. They point instead to a supply chain that can license land and growers faster than it can actually move product through the four-agency approval sequence described above. The licensing apparatus and the export apparatus are, in effect, running at two completely different speeds, and the gap between them is where nearly all of the projected revenue is disappearing.

New Rules, New Friction: Brazil and the FNE's 2026 Circular

Photo by Ali Mkumbwa via Unsplash.

Just as exporters were adjusting to the domestic friction created by Decree 1138, a separate regulatory shift arrived from the FNE that reshaped how Colombian cannabis derivatives reach one of the region's largest patient markets. External Circular 001 of 2026, published January 20, 2026, changed export procedures specifically for shipments of cannabis derivatives going to individual patients in Brazil.

The circular reflected a conclusion the FNE had reached internally: it could no longer issue the traditional export certificate it had previously used for these Brazil-bound, individual-patient shipments. In its place, exporters now have to apply for what's called a Concepto de Fiscalización -- essentially a separate fiscal/regulatory review -- before the FNE will issue the export visa that actually lets a shipment move. It's an added step inserted into a process that, for many exporters, had already cleared every other domestic hurdle.

The timing matters because Brazil isn't a marginal market for Colombian cannabis derivatives -- it's one of the largest individual-patient import markets anywhere in Latin America, built on a regulatory framework that allows Brazilian patients to import cannabis products for personal medical use with a doctor's authorization. Any added friction in that specific export lane ripples directly through Colombian exporters' revenue projections, since Brazil-bound shipments represent a meaningful share of the commercial activity that does manage to clear Colombia's domestic approval chain.

What the circular really illustrates is something exporters have learned to plan around: the rules don't stay fixed even after a shipment's domestic paperwork is otherwise complete. A company can spend months securing cultivation licenses, RNCC registration, INVIMA sanitary approval and ICA phytosanitary sign-off, only to find that the final export authorization step has been redefined by a new circular issued with a few weeks' notice. That kind of late-stage rule change is arguably harder to plan around than a slow bureaucracy -- at least a slow process is predictable.

How Exporters Are Routing Around the Jam

Photo by fernandozhiminaicela via Pixabay.

Faced with a four-agency chain that can stall a harvest indefinitely, Colombian exporters aren't trying to bypass ICA or the FNE -- there's no legal shortcut around mandatory phytosanitary certification or export quota authorization. What they're doing instead is building compliance infrastructure robust enough that approvals move faster once requested and survive scrutiny on the other end, in markets that increasingly ask for more documentation than Colombia's baseline licenses provide.

One signal of where regulatory thinking is headed came from ICA itself. The agency has had a draft resolution circulating since early 2025 that would open a formal pathway for importing dried cannabis flower from Canada. Paula Andrea Cepeda Rodriguez, ICA's general manager, confirmed the draft and noted something easy to miss: Colombia has technically permitted cannabis imports since 2016, the pathway has simply never been operationalized in practice. No Canadian imports have actually been approved under this framework yet, but the fact that ICA is working on import infrastructure at all suggests the agency sees itself managing two-way trade, not just export gatekeeping -- a posture shift that may eventually ease pressure on the export side too, if resources get allocated accordingly.

On the exporter side, the more immediate strategy is investment. Companies that are actually getting product abroad are putting money into EU-GMP grade processing facilities and full batch-record traceability systems -- platforms like GrowerIQ that log cultivation and processing data at a granularity well beyond what Colombian law strictly requires. European buyers, in particular, now expect documentation that goes past the country's baseline licensing standard, and exporters who can produce it tend to move through INVIMA and ICA review faster because there's less back-and-forth over missing records.

None of this solves the banking problem sitting underneath all of it. Many international banks still decline to process payments tied to cannabis exports, full stop, regardless of how clean a company's regulatory paperwork is. An exporter can have every government approval in hand and still struggle to get paid because a correspondent bank somewhere in the transaction chain has a blanket policy against cannabis-linked transfers.

Where the Real Bottleneck Has Moved

Photo by Cord Allman via Unsplash.

Talk to enough people in this industry and you start hearing the same reframe: the real constraint on Colombian cannabis exports isn't demand from destination markets anymore -- it's whether origin-country infrastructure can meet pharmaceutical-grade standards at scale. Buyers in Germany, the UK, and Brazil aren't short on interest in Colombian flower and extracts. What's short is the number of Colombian operations that can document GMP-grade consistency batch after batch.

Colombia's agronomic case was never the weak link. Equatorial daylight gives growers consistent light cycles essentially year-round, labor costs remain low relative to North American or European competitors, and the country can run multiple outdoor harvest cycles annually in regions that never see the production-limiting swings growers in temperate climates deal with. Those advantages are real and durable. What's missing is uniform GMP infrastructure across the licensee base -- the 2,982 operators who aren't among the 18 currently exporting mostly lack the processing, documentation, and quality-control systems that foreign regulators and buyers are now asking for as a baseline, not a bonus.

That's what makes Decree 1138's five-month clock on ICA's new technical regulations worth watching closely. It's effectively a stress test of whether a single agency can modernize its review capacity fast enough to match the ambitions of thousands of licensees who got into this industry expecting export revenue, not five more years of paperwork. If ICA hits that deadline with a workable technical framework, cultivar registration and phytosanitary review could start moving in parallel with other approvals instead of strictly in sequence.

Until that happens -- until cultivar registration, phytosanitary review, and FNE quota authorization stop being four sequential gates and start functioning as parallel tracks -- Colombia's export numbers are going to keep trailing its licensing numbers by orders of magnitude, no matter how much hectare capacity sits approved and unplanted.

It's worth being precise about what actually went wrong here, because the easy narrative -- that Colombia overpromised on cannabis reform -- isn't quite right. The country's cultivation law is genuinely permissive, its growing conditions are genuinely excellent, and its licensing pipeline has processed thousands of applicants without much controversy. The failure sits entirely in administrative sequencing: four agencies with different mandates, different staffing levels, and different review speeds, none of which are required to move in step with one another. A harvest can clear the Ministerio de Justicia and the Ministerio de Salud in reasonable time and then sit indefinitely waiting on an RNCC cultivar listing or an FNE quota approval that has nothing to do with whether the plant itself was grown legally.

The EU-GMP and traceability investments that surviving exporters are making right now aren't a temporary workaround -- they're almost certainly becoming the permanent cost of entry into this industry, independent of whatever happens with ICA's backlog. Foreign buyers aren't going to stop asking for batch-level documentation once Colombia's bureaucracy gets faster, if it does. Companies that build that capacity now are positioning themselves for a market that was always going to demand it eventually.

The single clearest near-term signal to watch is whether ICA actually meets its five-month deadline under Decree 1138 to publish workable technical regulations. Hit that deadline with a framework that lets cultivar registration and phytosanitary review run alongside each other rather than strictly in sequence, and the bottleneck starts easing in a way the export numbers should reflect within a year or two. Miss it, or publish something vague enough to generate another round of interpretive disputes, and the gap between 15,000 licensed hectares and 17 planted ones risks becoming simply how the Colombian cannabis industry works, rather than a problem anyone expects to fix.